Opendata, web and dolomites

BADGER SIGNED

CalScreener® – an innovative device for Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BADGER project word cloud

Explore the words cloud of the BADGER project. It provides you a very rough idea of what is the project "BADGER" about.

susceptibility    ast    antibiotics    setting    healthcare    gt    meet    sensitivity    efficient    though    device    introduce    rapid    clinicians    settings    suitable    clinically    hetero    diagnoses    stewardship    foundation    resistant    ill    correct    patient    diagnostic    prescribing    vitro    speed    antimicrobial    segment    combination    break    badger    designed    tools    diagnostics    accuracy    extensively    assays    infections    near    calorimetry    accurate    service    combat    broad    calscreenertm    smartly    solution    treatment    commercial    intend    antibiotic    clinical    provides    calorimetric    contributes    paradigm    bioenergetics    lack    decisions    daily    critically    causing    date    misuse    mic    lay    validate    sepsis    readily    line    personalized    multichannel    inappropriate    sold    strains    validating    cell    commercializing    amr    symcel    isothermal    micro    patients    specificity    resistance    pharmaceutical    tool    pure    first    redefine    time    assay    packaged    overuse    perform    cellular   

Project "BADGER" data sheet

The following table provides information about the project.

Coordinator
SYMCEL AB 

Organization address
address: DOMNARVSGATAN 4
city: SPANGA
postcode: 163 53
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://symcel.com/h2020-ast-combination-testing/
 Total cost 3˙572˙567 €
 EC max contribution 3˙572˙567 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYMCEL AB SE (SPANGA) coordinator 3˙572˙567.00

Map

 Project objective

SymCel provides a novel cell-based assay tool for real-time cellular bioenergetics measurements. Our key product, the calScreenerTM, is the first multichannel calorimetric system specifically developed for cell-based assays, which to date has been sold to the pharmaceutical research segment only. Even though calorimetry is a highly advanced research tool, it is considered not suitable for broad scale uptake into daily clinical practice. Through the BADGER project we intend to break this paradigm by validating and commercializing an in vitro diagnostic tool, that is based on isothermal micro calorimetry, for determining MIC for antimicrobial susceptibility testing (AST) of hetero-resistant sepsis causing strains. By providing a tool for the easy, correct and timely diagnoses of hetero-resistant and extensively resistant infections, we will redefine the commercial application segment for calorimetry systems (from pure research settings -> near patient diagnostics) and take AST to a new level of accuracy and speed. The clinical importance of AST is increasing in line with the growing concerns over antimicrobial-resistance (AMR) and the misuse of antibiotics. Lack of a rapid, low-cost and readily available solution contributes to the inappropriate prescribing and overuse of antibiotics. Clinicians are in need of an accurate and rapid diagnostic test to increase antibiotic stewardship, introduce combination treatment for critically ill patients and help combat AMR. The calScreenerTM will meet the users’ needs by providing a reliable diagnostic tool with high speed, specificity, and sensitivity in a smartly designed and packaged device with the tools available to perform testing in a near-patient setting. In all, the Phase 2 project will lay the foundation to clinically validate the calScreenerTM which will improve diagnostic decisions, provide a higher service level for patients, combat AMR and allow for more personalized and cost-efficient approaches to healthcare.

 Deliverables

List of deliverables.
Project subpage on corporate website Websites, patent fillings, videos etc. 2020-03-04 09:46:23
Ethics approval for Clinical study no. 2 Documents, reports 2020-03-04 09:46:23
Ethics approval for Clinical study no. 1 Documents, reports 2020-03-04 09:46:23
Ethics approval for Clinical study no. 3 Documents, reports 2020-03-04 09:46:23

Take a look to the deliverables list in detail:  detailed list of BADGER deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BADGER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BADGER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More